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Abstract
Here we demonstrate that a small panel of variants of cytochrome P450 BM3 from Bacillus
megaterium covers the breadth of reactivity of human P450s by producing 12 of 13 mammalian
metabolites for two marketed drugs, verapamil and astemizole, and one research compound. The
most active enzymes support preparation of individual metabolites for preclinical bioactivity and
toxicology evaluations. Underscoring their potential utility in drug lead diversification, engineered
P450 BM3 variants also produce novel metabolites by catalyzing reactions at carbon centers
beyond those targeted by animal and human P450s. Production of a specific metabolite can be
improved by directed evolution of the enzyme catalyst. Some variants are more active on the more
hydrophobic parent drug than on its metabolites, which limits production of multiply-hydroxylated
species, a preference that appears to depend on the evolutionary history of the P450 variant.
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Introduction
Selective C-H oxidation represents one of the great challenges for which synthetic chemists
find only very substrate-specific solutions.[1-4] Breakthroughs in selective C-H oxidation
methodology could benefit drug discovery, among other fields, by enabling rapid and
parallel analog construction for a specific molecular scaffold. Such improvements in
efficiency would greatly increase the number and variety of compounds that could be
produced, increasing the likelihood of identifying effective therapeutic agents.
Many synthetic strategies for C-H oxidation rely on a reactive intermediate that plays upon
subtle differences in C-H bond strength (1-5 kcal/mol) to achieve regioselectivity.[5] Owing
to the large number of C-H bonds in most bioactive chemicals, identifying a reagent that can
react at one C-H bond in preference to all others can be difficult, or even impossible. Nature
solves the selectivity problem by incorporating discrete molecular recognition elements into
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variants of a single bacterial P450 screened in 96-well plates produced nearly all the known human metabolites for three different
drugs as well as many new metabolites, often with high conversion and selectivity.
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enzyme catalysts so that they can use specific enzyme-substrate interactions to impart
reactivity to a specific C-H bond.
Cytochromes P450 (CYPs) are a large superfamily of heme-containing C-H oxidation
enzymes. In humans, CYPs play key roles in drug metabolism and clearance. An ability to
predict how potential pharmaceuticals will be metabolized will better equip us to identify
derivatives with improved biological activity, solubility, toxicity, stability or
bioavailability.[6] In fact, FDA guidelines indicate that uniquely human metabolites and
metabolites present at disproportionately higher levels in humans as compared to the animal
species used during standard toxicology testing may require safety assessment before
beginning large-scale clinical trials.[7]
Preparation of these metabolites at sufficient scale for evaluation is non-trivial and often
requires a de novo synthesis for each metabolite. Biosynthetic methods that employ purified
human CYPs or crude liver microsomes are not much better, because human CYPs are
poorly stable, membrane-bound, multi-protein systems that exhibit low reaction rates. As an
alternative to using human CYPs as biocatalysts for metabolite production, we and others
have focused on soluble, bacterial P450 BM3 (also known as CYP102A1)[8] as a C-H
oxidation platform.[9-11] Derived from Bacillus megaterium, P450 BM3 has properties that
greatly facilitate its engineering and use in synthesis: it can be expressed at high levels in
recombinant E. coli (~12% dry cell mass), and, unlike nearly all other CYPs, its
hydroxylase, reductase and electron transfer domains are all in one contiguous polypeptide
chain. This last feature may contribute to its relatively high activity (>1000 turnovers/min)
on its preferred fatty acid substrates.[8] Like most CYPs implicated in anabolic pathways,
P450 BM3 is substrate-specific, hydroxylating a C-20 fatty acid over a C-12 fatty acid with
more than 200 fold higher efficiency.[12]
We chose three structurally diverse drug compounds with known patterns of mammalian
CYP-dependent clearance to evaluate whether P450 BM3 variants can catalyze similar C-H
oxidations. Verapamil is a calcium channel blocker used in the treatment of hypertension
and arrhythmia.[13] Astemizole is a potent H1-histamine receptor antagonist used for
treatment of common sinus allergy symptoms.[14] The third compound, LY294002, is an
antiproliferative that inhibits phosphatidylinositol 3-kinase, a target with potential for
treatment of malignancies.[15] We report here that a small collection of P450 BM3 variants
can produce nearly all the known human (or rat) metabolites for each of the three drugs.
Within each set of active enzyme variants, we identified several that produce selected
metabolites in yields and activities suitable for preparative scale synthesis. We also
identified variants that generate metabolites not produced by rat liver microsome controls
nor known to be human metabolites, demonstrating the ability of this C-H oxidation
platform to target a range of carbon centers.
Results
Selection of P450 Variants
From our extensive collections we selected 120 P450 BM3 variants that had previously
demonstrated activity on substrates not in the wildtype enzyme’s repertoire. These variants
were constructed using a variety of commonly implemented genetic diversification
techniques, including error-prone PCR and targeted mutagenesis of active site residues. We
also included variants derived from structure-guided recombination of BM3 and its
homologs CYP102A2 and CYP102A3 to produce chimeric enzymes.[16] These enzymes had
been selected based on their activities towards a variety of substrates, including straight
chain alkanes, cycloalkanes, alkyl ethers,[17-19] aromatic compounds,[20] derivatives of fatty
acids,[21] and drugs.[10, 22]
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We also distinguished between enzyme variants that function as monooxygenases, using
NADPH to reduce the catalytic Fe(III) center, and peroxygenases that contain only the heme
domain and use H2O2 in place of O2 and NADPH. Each has its own catalytic and
operational advantages and disadvantages that have been described elsewhere.[21] Though
we had evidence that the presence of a reductase domain impacts activity favorably,[20] we
were unsure what effect, if any, this domain would have on regioselectivity. The variants,
their sequences relative to wildtype, and the criteria for their prior selection from mutant
libraries are described in Supplementary Table 1.
Reactions with Human and Bacterial CYPs
Verapamil and astemizole undergo extensive biotransformation by the major human CYPs
to produce demethylated and dealkylated products[23] by hydroxylation of activated carbon
centers adjacent to heteroatoms (summarized in Tables 1A, 2A). Experiments conducted
with rat liver microsomes in vitro indicate that LY294002 metabolism is confined to single
and double alkyl hydroxylations of the morpholine ring (Table 3), a pattern also observed in
other drugs possessing this moiety.
Reactions of the 120 P450 BM3 variants with each of the three drugs were assessed by
HPLC. Metabolite products were evident in the HPLC traces for a significant number of
variants (43 exhibited some activity on verapamil, 42 on astemizole and 18 on LY294002);
the metabolites and their distributions were subsequently characterized using LCMS and
MS/MS (Supplementary Tables 3, 4 and 5). Metabolite structure assignments were aided by
comparison of MS and MS/MS spectra with spectra of known metabolites obtained in our
laboratories using rat microsomal systems.
Verapamil—Table 1 summarizes the performance of selected enzymes on verapamil (all
43 active enzymes and their product distributions are listed in Supplementary Table 3). For
example, Entry 4 displays the activity of chimera 22313333 on verapamil. It converts 34%
of the starting material into an assortment of products, the distribution of which is 40% 2,
15% 5, 21% 6, 9% 7 and 15 % 10. Variants 2C11 and 9C1 furnished the widest array of
products, with 6 and 8 individual metabolites respectively. In particular, 9C1 produced
several metabolites that had undergone two hydroxylation events (1, 4 and 8). Variant
22313333 (Entry 4) was the only enzyme capable of producing double hydroxylation
product 5, while 32313233 (Entry 6) best produced norverapamil 3. Interestingly, the
addition of reductase as a fusion to the 32313233 heme domain (Entry 7) rendered the
enzyme unable to produce new metabolite 7. 7-11D (Entry 13) differs by no more than two
mutations from the variants in each of Entries 9-12, but its product distribution more closely
parallels chimera 21312332. The 9-10A family of enzymes was the most active, with
conversions exceeding 30% (Entries 9-12), and produced metabolite 7 with excellent
selectivity.
The enzymes that best mimicked human CYP reactivity on verapamil were derived from
two variant families. Three had been isolated by directed evolution for activity on
propranolol,[22] while the remaining four were chimeras.[16, 24] The BM3 variants that best
produced new metabolites were derived from the alkane-hydroxylating 9-10A variant.[18, 19]
These enzymes catalyzed a new regioselective demethylation reaction at position R4 and a
new benzylic oxidation at position R3. Even without optimization of the reaction conditions,
some enzymes were highly active on verapamil: D6H10 (Entry 3), for example, transformed
verapamil into metabolites at 78% conversion and a total turnover number (TTN) greater
than 1500.
The enzymes possess contrasting degrees of regioselectivity. Some were non-selective,
producing a spectrum of metabolites (e.g. propranolol-evolved enzymes 2C11, 9C1,
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D6H10). By contrast, chimera 22313231 produced norverapamil 2, chimera 32313233-R1
made dealkylated compound 6 (Entries 5 and 7), and many variants produced new
metabolites 7 and 10 (Entries 8-13) with sufficient selectivity (≥30%) for larger scale
production without further optimization. To demonstrate that useful quantities of metabolites
can be produced, we used purified 9-10A F87L and used it to produce metabolite 7 (9.4 mg)
from verapamil (25 mg) in 39% yield (1560 TTN, 0.025 mol% catalyst).
Astemizole—Activity of the enzyme panel on astemizole resulted in the seven metabolites
described in Table 2 (all 42 active enzymes and their product distributions are listed in
Supplementary Table 4). Variants DE10, 21313311, 22313333, 323313233 (Entries 1, 2 3
and 10) produced dealkylated metabolite 14 in preference to other compounds. The identity
of the residue at position 78 had a strong impact on the product distribution within the
9-10A backbone; mutations at A78F, A78T and A78S (Entries 4, 5 and 13) produced
metabolites 11, 13 and 15 as the most abundant respective products. Furthermore, 41-5B
(Entry 8), a 9-10A family member which contains the A78F mutation (in addition to A82G
and A328V), also favors demethylated 11. 9-10A A82S and 9-10A F87L both produced
metabolite 13 in good yield and selectivity (Entries 6 and 7). Two chimeric
monooxygenases, 32313233-R1 and 32312333-R1 (Entries 10 and 11), were effective in
generating new aromatic hydroxylation product 15.
The 9-10A-derived monooxygenases were the most adept at producing human metabolites
of astemizole (Entries 4-8). However, these enzymes were unable to dealkylate astemizole
and produce metabolite 14. Oxidation of this more hindered C-H bond was best
accomplished by the propranolol-active variants and chimeric peroxygenases (Entries 1 and
2, 3, respectively). A new benzylic site not hydroxylated by human CYPs was targeted by
six chimeric BM3 enzymes to produce 17. A second benzimidazole site was hydroxylated
(as demonstrated by metabolites 15 and 16), which is different from that observed in human
metabolites 12 and 13. Discrimination of these sterically and electronically identical sp2 C-H
bonds is virtually impossible using traditional transition metal catalysts and emphasizes the
power of molecular recognition as a regiocontrolling element.
Small changes in the substrate channel can affect the regioselectivity of aromatic C-H
oxidation. For instance, the presence and position of a single methyl group in Thr78 vs.
Ser78 (Entry 5 vs. 12) and Ile82 vs. Leu82 (Entry 14 vs. 13) were sufficient to bias oxidation
at C6 instead of at another position on the benzimidazole ring. Product 16 has undergone
two oxidations. Though this metabolite was observed in reactions with 10 variants, it was
produced in greater than 10% abundance by only one (Entry 4). New metabolite 15 is a
candidate for scale up and could be produced at high conversion (>25% selectivity) by 15
variants of different lineages (Supplementary Table 4). Even without optimization of
reaction conditions, several enzymes showed good activity towards astemizole. Variant
32312333-R1, for example, converted 78% astemizole into metabolites (70 TTN).
LY294002—The most abundant metabolites produced by rat liver microsomes are detailed
in Table 3. Both single hydroxylation products 19 and 20 were identified in BM3 variant
reactions with very good regioselectivity. Aminoalcohol 18 is the sole metabolite of all three
drugs not observed in the reactions. Derivative 18 requires two oxidations and may not
appear simply due to the low conversion in these 96-well plate reactions.
The P450s catalyzing the single hydroxylations were monooxygenases derived from 9-10A
(Table 3). Though several variants could produce metabolite 19, only 9-10A F87V oxidized
the other position of the morpholine ring and made derivative 20 (Entry 3). The remaining
12 metabolite-producing variants were also monooxygenases, of both 9-10A and chimeric
origin, and produced a metabolite with Mw=238, indicating morpholine loss and addition of
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water to the bis-aryl backbone (Supplementary Table 5). In all cases, LY294002 conversion
was very low (<15%), which correlates with the low rat liver microsome conversion for
LY294002 (40%) relative to microsome activity on verapamil (85%) and astemizole (85%).
LY294002 better evades both mammalian and bacterial P450-catalyzed C-H oxidation than
verapamil and astemizole under the same conditions.
Activities On Singly-Hydroxylated Metabolites
Of the 12 mammalian metabolites produced by the P450 BM3 variants, eight were made
with sufficiently high selectivity to enable preparative scale production without further
optimization (2, 3, 6, 11, 13, 14, 19 and 20). Of the seven new metabolites to which
structures could be assigned, four were made with sufficiently high regioselectivity to enable
preparative scale production (7, 10, 15 and 17). All 11 of the highly produced metabolites
arose from single oxidations. Seven of the eight remaining metabolites are the products of
two or more oxidations and are present as minor components in mixtures with the singly-
hydroxylated products. Of the 69 individual reactions that underwent appreciable conversion
(≥10% drug consumed), only five generated products of multiple C-H oxidations in ≥10%
abundance.
The remainder contained single-oxidation products, including mixtures of singly-oxidized
species. The lack of bis-hydroxylated products could reflect a regiochemical effect in which
the second C-H site is less reactive. In this case, one of the two possible single-
hydroxylation products would be favored. Sixteen variants produced only one single-
hydroxylation product; reaction mixtures from 10 additional variants contained two
(metabolites were present in 1:1 to 3:1 ratios in 6/11 reactions). It is also possible that the
relative lack of bis-hydroxylation products reflects discrimination on the part of the
enzymes, in which the BM3 binds and hydroxylates the parent drug in preference to its
metabolites. Because BM3-catalyzed C-H oxidation increases polarity by either unmasking
heteroatoms or formally substituting hydrogen with a hydroxyl group, production of poly-
hydroxylated metabolites could be disfavored, for example, if the enzyme prefers a more
hydrophobic substrate.
To assess enzyme activity on the metabolites produced by a single oxidation, all 120
enzymes were incubated with purified demethylated metabolites norverapamil 3 and
desmethylastemizole[26] 11. Product distributions and extents of reaction were determined
by HPLC. In every case where an enzyme was active on both parent drug and metabolite,
regioselectivities were unchanged, indicating that the metabolite and parent drug bind in
similar orientations. Comparison of each enzyme’s activity on the parent drug and the
associated metabolite showed that enzymes from the alkane-evolved 9-10A lineage tended
to be more active on astemizole and verapamil than on their metabolites (true of 49 out of 55
active enzymes) (Table 4). Because neither the N-methyl group of verapamil nor the O-
methyl group of astemizole is the preferred site for C-H oxidation by the alkane-evolved
variants, this bias may reflect a preference for the more hydrophobic substrate. In contrast,
when this pairwise reaction matrix is analyzed across the propranolol-evolved and chimeric
P450 BM3 lineages, there is no statistical difference from random at the 95% confidence
interval (0.43 ≤ p = 0.60 ≤ 0.77).
Directed Evolution Can Improve Metabolite Production
None of the 120 members of this catalyst panel had been selected for activity on any of the
three drugs. Thus, any initial activity represents a promiscuous activity; such side activities
are often easy to improve by directed evolution.[27, 28] Of the 103 enzymes that reacted with
these substrates, 9-10A F87L possessed the best combination of activity and regioselectivity
(Table 2, Entry 7); its reaction with astemizole, which produces metabolite 13 with 88%
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selectivity, is representative of a reaction for which one would like to improve metabolite
production. We speculated that a high throughput screen for improved overall aromatic
hydroxylation activity would yield at least a few variants that retained this regioselectivity
while producing more metabolite. We screened 2,000 variants made by error-prone PCR of
the 9-10A F87L gene using a colorimetric screen for products of aromatic hydroxylation[29]
and identified three new sequences with improved metabolite production (Table 5). The new
variants improved the conversion to 51-52% while preserving high regioselectivity (~80%
for metabolite 13).
Discussion
A small, 120-member panel of P450 BM3 variants captured nearly all of the mammalian
P450 scope of reactivity by producing 12 of 13 known metabolites. In their ability to mimic
human CYPs, the P450 BM3 variants demonstrated considerable versatility, activating C-H
bonds of varying strength (90-105 kcal/mol) and steric encumbrance (sp2 vs. sp3 and 1° vs.
2° carbon centers). We were able to assign structures to 7 new metabolites (Tables 1B, 2B),
all of which have undergone oxidation at new carbon centers.
Cytochrome P450 enzymes are versatile catalysts whose biological activities are encoded in
a wide range of primary sequences. The 26 CYPs whose crystal structures have been solved
possess as little as 15% sequence identity,[30] but share a highly conserved fold.
Emphasizing the versatility of the P450 fold, P450cam and P450cin catalyze the oxidation
of isosteres camphor and cineole. Although the substrates are nearly identical, the two
enzymes differ not only in sequence (27% identity), but also in the structure of their active
sites, most notably a complete lack of the B’ helix in P450cin.[31, 32] Whereas large changes
in sequence are possible, only small perturbations are necessary to produce significant
changes in function. For example, CYP2A4 and CYP2A5 differ by only 11 amino acids, yet
catalyze hydroxylations on structurally dissimilar coumarin and testosterone substrates.[33]
Only 57 human enzymes[34] are responsible for known CYP-dependent drug metabolism,
and a single enzyme, CYP3A4, accounts for >50% of the burden for xenobiotic CYP-
mediated clearance.[35] Because CYPs can be broadly or narrowly specific, we and others
have speculated that it should be possible to take advantage of the high native activity of
P450 BM3 and use mutation to either relax or shift its substrate specificity in order to
generate useful C-H oxidation catalysts.[9, 36-39] For example, BM3 variant 9-10A, 13
mutations away from wildtype, exhibits broad activity across short- and medium-chain
alkanes, activity that is low or completely absent in its wildtype parent.[18, 19] Furthermore,
9-10A could be re-specialized to hydroxylate propane, preferring it over alkanes that differ
by a single methylene group.[40] We also showed previously that a variant of 9-10A was
able to hydroxylate drug-like compounds efficiently and selectively.[10] Here we wanted to
determine whether variants of 9-10A and other BM3-derived enzymes could cover or even
exceed the broad substrate range of mammalian CYPs. Within any catalyst panel, both
extremes of regioselectivity can be useful: enzymes that already possess the desired
selectivity can be used to produce individual metabolites, whereas less selective enzymes
can be used to survey metabolite possibilities. Both can serve as starting sequences for
directed evolution to enhance activity or tune selectivity. That a systematic and general
evolutionary algorithm can be used for catalyst improvement is a particularly appealing
aspect of DNA-encoded reagents. Complementary optimization studies used in traditional
synthetic methods usually rely on chemical intuition to improve a catalyst and require a
good understanding of the catalytic mechanism.
When we examined conversion of the parent drug versus its demethylated metabolite, we
noted that one enzyme family consistently converted more of the parent drug than the
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demethylated and more-polar metabolite. These enzymes tend to catalyze single
hydroxylations, while enzymes evolved for activity on propranolol and the chimeric variants
often catalyze bis-hydroxylations. Structure-activity relationships of this type should help in
the future to select enzymes that are most likely to react with as yet untested substrates and
may also help predict product profiles.
Conclusions
This panel should enable rapid identification and production of relevant quantities of the
human metabolites of drug candidates for pharmacological and toxicological evaluations in
preclinical species.[41, 42] Although we have highlighted the potential of these enzymes to
accelerate preparation of metabolites for pharmacological and toxicological testing, this
enzyme panel is likely also to be useful further upstream in the drug development process as
general reagents for lead diversification. Reagents that rely on molecular recognition will
always be restricted in their scope of use. However, because the functionality of small
molecules is not evenly distributed across all possible molecular architectures,[43] it should
be worthwhile to engineer P450-derived reagents that are active on privileged scaffolds that
reside in these densely functional regions of structure space. The plurality of C-H sites
targeted by this small P450 BM3 variant set—including and extending human P450
metabolism—augurs well for the development of a truly general panel of C-H oxidation
catalysts.
Experimental Section
All chemicals were purchased from Sigma-Aldrich, Inc. or provided by Eli Lilly directly.
Solvents were purchased from EM Sciences. Lysis enzymes were purchased from Sigma.
Absorbance measurements were conducted using a SpectraMax 384 Plus plate reader.
HPLC separations were performed using a Supelco Discovery C18 column (2.1 × 150 mm,
3μ on a Waters 2690 Separation module in conjunction with a Waters 996 PDA detector.
LCMS and MS/MS spectra were obtained using the ThermoFinnigan LCQ classic at the
shared Caltech MS facility.
Protein Expression
LB agar plates supplemented with 100 μg/mL ampicillin were streaked with the catalase-
deficient strain of E. coli SN0037[44] (for peroxygenase) or DH5α E. coli (for
monooxygenase) containing a desired P450 BM3 variant on the isopropyl β-D-
thiogalactopyranoisde (IPTG)-inducible pCWori vector.[45] These were grown at 37 °C for
12 h before single clones were picked and added in quadruplicate to 1 mL 96-well plates
containing 400 μL LB medium supplemented with 100 μg/mL ampicillin. After shaking at
80% humidity, 30 °C for 24 h to grow the pre-cultures to saturation, a 50 μL aliquot was
used to inoculate 2 mL 96-well plates containing 900 μL TB medium supplemented with
100 μg/mL ampicillin. After shaking at 80% humidity, 30 °C for 5 h, P450 expression was
induced by adding 500 mM IPTG and the heme precursor δ-aminolevulinic acid (δ -ALA) to
a final concentration of 1 mM. The cultures were grown for another 24 h before the cells
were pelleted and stored at −20 °C.
Activity-Based Screening
All three drugs and two metabolites were screened in against the cell lysate of the panel of
120 variants. Lysate was prepared by resuspending cell pellet with 600 μL of a buffer
containing 10 mM MgCl2, 0.5 mg/mL lysozyme and 8 U/mL DNAseI. Holoenzyme
reactions used 0.1 M phosphate, pH=8 as the buffer and peroxygenase reactions used 0.1M
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EPPS, pH=8.2 as the buffer. The lysis reactions were incubated at 37 °C for 1 h and then
spun down to use the supernatant in three assays:
CO-binding—Heme proteins absorb light at 450 nm corresponding to the CO stretch
frequency when the Fe-heme is bound to CO. This Soret band can be used to quantify the
amount of folded protein.[46] Conditions: To a 96-well flat bottom screening plate was
added lysate (100 μL), sodium dithionite (100 μL, 140 mM in 1 M buffer, pH=8). These
were pre-read on a plate reader at 450 nm and 490 nm before incubating in a 1 atm CO
chamber for 15 minutes. The plate was then read again at 450 nm and 490 nm.
Enzymatic Activity—To a 96-well deep well (2mL) plate, the following mixtures were
prepared for each of the activity-based assays: Holoenzyme: lysate (60 μL), phosphate (110
μL, 0.1 M, pH=8), drug/metabolite (10 μL, 5 mM), NADPH (20 μL, 20 mM).
Peroxygenase: lysate (50 μL), EPPS (100 μL, 0.1 M, pH=8.2), drug/metabolite (10 μL, 20
mM), hydrogen peroxide (40 μL, 5 mM).
Upon ultimate addition of NADPH or H2O2, the plates were briefly shaken and allowed to
react for 2 h. At this time, acetonitrile (200 μL) was added to quench the reaction. The
reactions were spun down and the supernatants used for subsequent analysis by HPLC and
LCMS.
HPLC—25 μL supernatant was analyzed by HPLC. Conditions with solvent A (0.2%
formic acid (v/v) in H2O) and solvent B (acetonitrile) used to elute the products of
metabolism were: 0-3 min, A:B 90:10; 3-25 min, linear gradient to A:B 30:70; 25-30 min,
linear gradient to A:B 10:90.
LCMS, MS/MS—Identical conditions to the HPLC method detailed above were used for
the LC portion of the analysis. The MS was operated in positive ESI mode. MS/MS spectra
were acquired in a data dependent manner for the most intense ions.
Preparation of Metabolite 7
To a 250 mL Erlenmeyer flask containing potassium phosphate buffer (50 mL, 100 mM,
pH=8.0) was added glucose-6-phosphate (80 mM), glucose-6-phosphate dehydrogenase (2
U/mL), superoxide dismutase (100 U/mL), 9-10A F87L (250 nM), verapamil (24.6 mg, 1
mM) and NADP (5 mM). These reagents were stirred vigorously at room temperature while
metabolite production was monitored every hour for 4 h by HPLC. The reaction was
quenched by precipitating the enzymes with acetonitrile (50 mL) and stirring an additional
30 min followed by filtration. The resulting solution contained 9.4 mg metabolite 7 (39%).
Directed Evolution of 9-10A F87L for Activity on Astemizole
Error-prone PCR was used to create the variant library. Cells containing the 9-10A F87L
template on a pCWori plasmid were grown and plasmid DNA isolated. Error prone PCR
reactions of volume 50 μl contained the following: water (38 μL), 10 × Applied Biosystems
PCR Buffer (5 μL), forward primer ggaaacaggatccatcgatgc (1 μL, 10 μM), reverse primer
gtgaaggaataccgccaagc (1 μL, 10 μM) and template plasmid (0.5 μl, 200 ng/μl), Taq
polymerase (1 μL, 5 U/μl), dNTP (1 μL, 10 μM) and MnCl2 (2.5 μL 1 mM). PCR conditions
were 95 °C for 5 min, followed by 30 cycles of 30 s a 95 °C, 60 s at 52 °C and 120 s at 72
°C. The PCR products were treated with DpnI to remove template DNA followed by
digestion with BamHI and SacI. Following agarose gel purification, the oligonucleotide
library was ligated into the pCWori vector and then electroporated into DH5α E. coli cells.
The transformants were plated on LB agar medium supplemented with 100 μg/ml of
ampicillin and grown at 37 °C over 16 h. Protein was expressed, as described in the Protein
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Expression portion of the Experimental section. Variant hits were identified by first
screening using a high throughput colorimetric assay for aromatic hydroxylation.[29] Cells
were lysed and prepared for reaction as described previously. Upon ultimate addition of
NADPH or H2O2, the plates were briefly shaken and allowed to react for 2h. At this time,
urea (60 μL, 8 M in 200 mM NaOH), 4-aminoantipyrine (18 μL, 1.2%) and potassium
peroxodisulfate (18 μL, 1.2%) were added. Absorption at 510 nm was measured after 10
min. Reactions containing variant enzymes more active than 9-10A F87L parent were
repeated and characterized by HPLC, LCMS and MS/MS as described previously. Validated
hits were sequenced.
Supplementary Material
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Table 4
Preference for more hydrophobic parent drug over its metabolite depends on evolutionary history of the
variant.
P450 Variant Family Number of P450s MoreActive on Parent Drug
Number of P450s More
Active on Metabolite
Alkane-selected lineage 49/55 6/55
Propranolol-selected and
 chimera lineages 18/30 12/30
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Table 5
Production of astemizole metabolites by 9-10A F87L variants.
Variant % Conversion % Selectivity 13
1 9-10A F87L 34 88
2 E4D D68G 51 80
3 C205R D338G 51 80
4 E4D H92Q 52 75
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